06/19/19

Stereotactic Radiosurgery (SRS), a bloodless, non-invasive surgery involving the use of extremely focused beams of high doses of radiation to destroy cancer abnormalities within the brain, is once again being offered exclusively on the Eastern Shore of Maryland at Peninsula Regional Health System’s Richard A. Henson Cancer Institute Ocean Pines.

SRS was first performed on Delmarva at the Richard A. Henson Cancer Institute at Peninsula Regional Medical Center (PRMC) in 2002, but suspended nearly a half-decade ago when the manufacturer of the device discontinued production of components. Now, thanks to the addition of the PerfectPitch Six Degrees of Freedom Couch, which aids in radiation treatment, SRS is being offered again at PRMC’s Ocean Pines Health Pavilion.

“Stereotactic Radiosurgery uses linear accelerator driven radiation beams that are directed by neurosurgical stereotactic guidance technology, providing a very tightly conformed high dose single treatment that is administered with near perfect location control to obliterate the cancer and have much less impact on surrounding brain tissue” said, John Mansueti, MD, Medical Director of Radiation Oncology

Stereotactic Radiosurgery is a procedure used to treat brain abnormalities including those that may be inaccessible or unsuitable for conventional neurosurgical or radiation therapy techniques. Patients who are candidates for SRS will first have a CT scan and an MRI performed to allow physicians to determine the exact location of the abnormality within their brain.

While the patient rests comfortably on the center’s PerfectPitch Six Degrees of Freedom Couch, radiation oncologists and treatment planners design the care using sophisticated computers to detail the target area, target volume, plus the dosage, direction and length of the radiation treatment beams. The couch allows them to set patients up with extreme accuracy, which will spare more normal tissue to radiation exposure.

Once treatment begins, precise radiation arcs are “fired” directly into the center of the abnormality within the brain.

“The fact that this procedure is performed outpatient in our cancer institute is a terrific benefit,” stated Dr. Mansueti. “Most importantly, it provides us a treatment option for those people who otherwise didn’t have that choice locally for a number of years.”

Most patients notice results of the procedure immediately after their first and only treatment. Initially, following Stereotactic Radiosurgery, the abnormality will stop growing. Over time, it will shrink and, in most cases, disappear within several months.

Dr. Mansueti estimates up to 2-3 patients per month could qualify for the procedure, which is also scheduled to be available again at the Richard A. Henson Cancer Institute in Salisbury within a year.